Clinical trials: Oral Infection
Vulvovaginitis, Yeast Infection
Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)
This is a multi-center, randomized study to evaluate the safety, tolerability, and efficacy of 200 mg CAMB and 400 mg CAMB compared with a single 150 mg dose of fluconazole in the treatment of moderate to severe VVC.
- Conditions
- Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
- Trial name
- NCT02971007
- Testing
- Oral Encochleated Amphotericin B (CAMB), Fluconazole
- Where
- 23 sites in United States
- Volunteers
- 137 people
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Varicella, Rubella
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00969436
- Testing
- GSK Biological's investigational MMRV vaccine 208136, Priorix™, Varilrix™
- Where
- 6 sites in India
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bronchitis
Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup
Objectives: The objectives of the study was to investigate the bioequivalence between two formulations containing S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys) when administered as single oral dose in two…
- Trial name
- NCT02858193
- Testing
- SCMC-lys powder 1.35 g, Fluifort® syrup
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dompé Farmaceutici S.p.A
Chronic Hepatitis C
Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Background: Chronic hepatitis C is a serious liver disease. Current treatments have side effects. New drugs have been developed, but they work better in some people than others. Researchers want to learn why.
- Trial name
- NCT02468648
- Testing
- Sofosbuvir, GS-5816
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Malaria
Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets
This is a single-centre, 2-part, randomised, single-dose parallel group study in healthy male subjects and female subjects of non-childbearing potential.
- Trial name
- NCT02387580
- Testing
- OZ439 + TPGS, OZ439 Prototype 1, OZ439 Prototype 3
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Hepatitis C, Medication Adherence
Intensive Models of HCV Care for Injection Drug Users
Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival.
- Trial name
- NCT01857245
- Testing
- Intensive Models (mDOT and CGT) of HCV Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Prisma Health-Upstate
Pneumonia
Improving Oral Care to Reduce Hospital-Acquired Pneumonia (HAP) in the Acute Neurologically Impaired Adult
Hypothesis: The investigators hypothesize that the current oral protocol is sub-optimal and an enhanced protocol will decrease the incidence of hospital acquired pneumonia (HAP)in the acute, non-intubated, care-dependent…
- Trial name
- NCT01498601
- Testing
- Enhanced oral care protocol
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Fraser Health
Gonorrhea
Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea
The purpose of this study is to evaluate the effects of a single oral dose of delafloxacin versus a single intramuscular injection of ceftriaxone in subjects with uncomplicated cervical, urethral, rectal, or pharyngeal gonorrhea.
- Trial name
- NCT02015637
- Testing
- Delafloxacin, Ceftriaxone
- Where
- 25 sites in United States
- Volunteers
- 460 people
- Sponsor
- Melinta Therapeutics, Inc.
Invasive Fungal Infections, Hematologic Malignancies
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
The objective of this study is to compare the safety and efficacy of ABLC versus oral Posaconazole in the prevention of invasive fungal infections in high risk patients with hematologic malignancies or hematopoietic stem cell…
- Trial name
- NCT00750737
- Testing
- Posaconazole, ABLC
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients
Respiratory Syncytial Virus - RSV Protocol
The goal of this clinical research study is to learn if ribavirin can help to control RSV in patients with immune systems that have been weakened by a stem cell transplant.
- Conditions
- Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia
- Trial name
- NCT01502072
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Upper Respiratory Infection, Acute Otitis Media
Lactobacillus Rhamnosus GG in the Middle Ear and Adenoid Tonsil
The purpose of this study is to evaluate the effect of oral administration of probiotic Lactobacillus rhamnosus GG in middle ear and adenoid tonsil.
- Trial name
- NCT02110732
- Testing
- Lactobacillus rhamnosus GG
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Herpes Labialis
Phase 3 Clinical Study for the Treatment of Cold Sore
To demonstrate the efficacy of a single dose of acyclovir Lauriad® 50mg muco-adhesive buccal tablet versus a single dose of matching placebo on the primary vesicular lesion of cold sore.
- Trial name
- LIP (NCT00769314)
- Testing
- Acyclovir Lauriad
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 1,727 people
- Sponsor
- Valerio Therapeutics
Mycoses, Candidiasis, Invasive
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
The purpose of this study is to compare the safety, pharmacokinetics, and efficacy of oral SCY-078 vs. standard-of-care following initial intravenous echinocandin therapy in the treatment of invasive candidiasis.
- Conditions
- Mycoses, Candidiasis, Invasive, Candidemia
- Trial name
- NCT02244606
- Testing
- SCY-078, Fluconazole, Micafungin
- Where
- 30 sites in United States, El Salvador and 3 more
- Volunteers
- 27 people
- Sponsor
- Scynexis, Inc.
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis
- Trial name
- NCT01595438
- Testing
- Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
- Where
- 80 sites in United States, Argentina and 20 more
- Volunteers
- 598 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
This is the first study of oral tofacitinib in adults with active ankylosing spondylitis. It is designed to obtain information on the efficacy and safety of 3 different doses of tofacitinib.
- Trial name
- NCT01786668
- Testing
- Tofacitinib 2 mg, Tofacitinib 5 mg, Tofacitinib 10 mg
- Where
- 67 sites in United States, Canada and 8 more
- Volunteers
- 208 people
- Sponsor
- Pfizer
Kaposi´s Sarcoma
Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi sarcoma remains the most common malignancy among persons with HIV. Lesions localized to the airway may cause bleeding, pain and dyspnea. New therapeutic approaches for local disease are needed.
- Trial name
- NCT01296815
- Testing
- Bevacizumab
- Where
- Mexico
- Volunteers
- 14 people
- Sponsor
- Centro de Investigación en. Enfermedades Infecciosas, Mexico
Clostridium Difficile Infection, Diarrhea
TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
The purpose of this study is to determine the risks and benefits of antibiotic treatment for Clostridium difficile infection (CDI) among patients whose stool samples are nucleic acid amplification test (NAAT) positive and enzyme…
- Trial name
- NCT03388268
- Testing
- Oral Vancomycin, Toxin enzyme immunoassay, Nuceleic acid amplification test
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Chronic Hepatitis C
Study of Oral Treatments for Hepatitis C
Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions.
- Trial name
- PRIORITIZE (NCT02786537)
- Testing
- SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir)
- Where
- 38 sites in United States
- Volunteers
- 1,275 people
- Sponsor
- University of Florida
Respiratory Syncytial Virus
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
This was a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with RSV infection.
- Trial name
- RSVP (NCT04196101)
- Testing
- EDP-938
- Where
- 29 sites in United States, Argentina and 5 more
- Volunteers
- 82 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Herpes Labialis
Botulinum Toxin A for Herpes Labialis
The purpose of this study is to determine the efficacy and safety of Botulinum Toxin Type A as a preventative measure for Herpes Labialis.
- Trial name
- NCT01225341
- Testing
- onabotulinumtoxinA, Bacteriostatic normal saline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- DeNova Research